Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06735248 · ClinicalTrials.gov registry record · Phase 2

A Study to Investigate Multiple Sclerosis Relapse Prevention With mRNA-1195 Compared With Placebo in Participants Aged 18 to ≤55 Years

A Phase 2 study of Multiple Sclerosis, sponsored by ModernaTX.

Recruiting
Registry status
Phase 2
Development phase
180
Enrollment target
17
Study locations

NCT06735248 is a Phase 2 study of Multiple Sclerosis that is actively recruiting participants, run by ModernaTX. The registered enrollment target is 180 participants, below the 584-participant average among 315 other Multiple Sclerosis trials with a reported enrollment target (69% lower). The trial reports 17 study locations across 7 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06735248, a Phase 2 study of Multiple Sclerosis, is actively recruiting participants, sponsored by ModernaTX.

RECRUITING
Registry status
Phase 2
Development phase
180 participants
Enrollment target
17
Study locations

Study Summary

The primary objective of this trial is to evaluate the safety and reactogenicity of mRNA-1195 in participants with multiple sclerosis.

Conditions Studied

Multiple Sclerosis

Interventions

  • BIOLOGICAL Placebo
  • BIOLOGICAL mRNA-1195

Study Locations (17)

Other

  • North Bristol NHS Trust - Southmead Hospital - Bristol
  • Cardiff and Vale University Health Board - University Hospital Wales - Cardiff
  • Anne Rowling Regenerative Neurology Clinic, University of Edinburgh - Edinburgh
  • NHS Greater Glasgow & Clyde - Institute of Neurological Sciences - Glasgow
  • Cambridge Clinical Research Centre - London
  • East Kent Hospitals University NHS Foundation Trust - London
  • The Newcastle Upon Tyne Hospitals NHS Foundation Trust - Newcastle upon Tyne
  • Sheffield Teaching Hospital NHS foundation Trust, Herries Road - Sheffield

Texas

  • University of Texas Southwestern Medical Center - Dallas
  • ANESC Research - El Paso
  • Saturn Research Solutions - Plano

Missouri

  • Sharlin Health & Neurology - Ozark
  • Washington University School of Medicine Neurology Clinical Unit - St Louis

Massachusetts

  • Boston Clinical Trials Inc - Internal Medicine - Boston

Michigan

  • Quest Research Institute - Farmington Hills

Oklahoma

  • Oklahoma Medical Research Foundation (OMRF) MS Center of Excellence - Oklahoma City

Queensland

  • University of the Sunshine Coast Clinical Trials - Birtinya

Trial Details

FieldValue
Enrollment Target 180 participants
Start Date 2025-04-16
Est. Completion 2029-01-08
Phase Phase 2

Sponsor

ModernaTX

90 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06735248

The ClinicalTrials.gov registry entry for NCT06735248 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 180 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 584-participant average among 315 other Multiple Sclerosis trials with a reported enrollment target (69% lower). The listed sponsor is ModernaTX, which has 90 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Multiple Sclerosis appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT06735248 reports 17 study locations spanning 7 distinct geographic areas - top geographies include Other, Texas, Missouri.

Frequently Asked Questions

What is clinical trial NCT06735248 about?

NCT06735248 is a clinical study titled "A Study to Investigate Multiple Sclerosis Relapse Prevention With mRNA-1195 Compared With Placebo in Participants Aged 18 to ≤55 Years". The primary objective of this trial is to evaluate the safety and reactogenicity of mRNA-1195 in participants with multiple sclerosis.

What is the current status of trial NCT06735248?

This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 180 participants. The study started on 2025-04-16. Estimated completion is 2029-01-08.

What conditions does trial NCT06735248 study?

This clinical trial studies the following conditions: Multiple Sclerosis.

What interventions are being tested in trial NCT06735248?

The interventions under investigation include: Placebo (BIOLOGICAL), mRNA-1195 (BIOLOGICAL).

Who is sponsoring clinical trial NCT06735248?

This trial is sponsored by ModernaTX, which has 90 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06735248 being conducted?

This trial has 17 study locations across Massachusetts, Michigan, Missouri, Oklahoma, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Multiple Sclerosis

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Multiple Sclerosis

All registered trials for this condition

Massachusetts

All trials with a study site in Massachusetts

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.